timothy sykes logo
MRNA Stock Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Heat Up Thumbnail
G Google News

MRNA Stock Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Heat Up

JACK KELLOGG•UPDATED OCT. 9, 2026, 12:32 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Moderna Inc. stocks have been trading up by 10.78 percent on optimism surrounding its latest mRNA vaccine developments.

Key Takeaways

  • Addition to the Nasdaq-100 on 2026/10/09 should drive passive fund buying in MRNA and boost visibility with large-cap growth traders.
  • Creation of a new Chief Operating Officer role and return of veteran executive Juan Andres signal Moderna gearing up to scale intismeran autogene and its five-vaccine infectious disease franchise.
  • Shares dropped roughly 6–7% after the COO news and retirement of manufacturing chief Jerh Collins, showing near-term nerves around execution risk.
  • Morgan Stanley and Evercore ISI nudged price targets to $95 and $80, while the Street sticks with mostly Hold ratings and a mean target around $116.84.
  • Expanded collaboration with Tempus and Merck pushes intismeran autogene closer to potential commercialization alongside Keytruda, tightening the focus on Moderna’s oncology story.

Candlestick Chart

Live Update At 12:32:26 EDT: On Friday, October 09, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 10.78%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has been trading like a momentum monster. Over the last few weeks, Moderna stock ran from the mid-$140s to above $210, then pushed to a recent close near $218. That’s a strong uptrend with higher highs and higher lows on the daily chart.

For active traders, this move shows clear accumulation. Pullbacks from $212–$205 kept finding buyers, and each dip has been getting bought faster. Intraday, MRNA opened just under $200, ripped through $210, and held most of those gains through midday — classic trend day behavior.

Under the hood, Moderna’s financials still look like a high‑risk, high‑reward biotech pivoting beyond its COVID boom. Revenue over the last year is about $1.92B, but growth is shrinking, and the company posted a recent quarterly net loss of roughly $782M with negative free cash flow of about $563M. Margins are deep in the red, yet the balance sheet carries around $5.14B in cash and short-term investments and modest debt, giving MRNA room to fund its pipeline.

More Breaking News

For traders, that combo — strong chart, heavy losses, big cash pile — usually means volatility. Catalysts matter more than traditional valuation right now.

Why Traders Are Watching MRNA Right Now

MRNA is back in the spotlight because the story has shifted from one-off COVID hero to a full platform and oncology player. The near-term spark is technical: Moderna is joining the Nasdaq‑100 on 2026/10/09, replacing Warner Bros. Discovery. Whenever a name gets added to that index, passive index funds and ETFs tracking it are forced buyers. That flow doesn’t last forever, but around the inclusion date it can act like a tailwind, especially when the chart is already trending up.

At the same time, the fundamentals narrative around MRNA is getting more layered. Moderna is expanding its infectious disease lineup to five approved vaccines, including a seasonal flu shot and a flu+COVID combo in Europe. That gives the company a more recurring, seasonal demand profile instead of just chasing pandemic waves. Traders looking at longer swings like seeing multiple revenue pillars.

The real wildcard is oncology. Positive data on Moderna’s therapeutic cancer vaccine and the CEO’s comments in the Wall Street Journal about a “disciplined” move into cancer and Alzheimer’s make it clear this is not a random pivot. MRNA spent years proving mRNA in simpler vaccines, then stepped up the risk curve. Now, intismeran autogene — an individualized cancer therapy — sits at the center of that push.

To support that, Moderna expanded its multi‑year collaboration with Tempus and Merck. Tempus will handle sample logistics and sequencing as the therapy is tested with Merck’s Keytruda in melanoma and other cancers. That signals partners are leaning in as intismeran autogene edges closer to potential commercialization. For momentum traders, that kind of strategic backing often fuels speculative runs ahead of bigger data and regulatory events.

Conclusion

The biggest controversy around MRNA in the short term is not the science; it’s execution. Moderna is creating a new Chief Operating Officer role and bringing back former senior executive Juan Andres to run global operations and manufacturing. That move lines up with the company’s ambitions: scale intismeran autogene if approved, support a broader oncology portfolio, and manage a five‑vaccine infectious disease franchise as COVID demand normalizes.

Traders didn’t cheer the headline at first. MRNA dropped roughly 6–7% in premarket and early trading on the COO announcement and the planned retirement of Chief Technical Operations and Quality Officer Jerh Collins. That knee‑jerk selloff reflects standard market anxiety — leadership transitions in complex manufacturing environments can get messy.

Yet Wall Street isn’t walking away. Morgan Stanley raised its MRNA target to $95 with an Equal Weight stance, while Evercore ISI bumped its target to $80. The broader analyst crowd still sits at an average Hold rating with a mean target near $116.84. That’s cautious optimism, not euphoria.

For active traders, MRNA is a classic catalyst setup: strong trend, heavy news flow, and real fundamental uncertainty. As Tim Sykes likes to say, “Volatility is the trader’s best friend — as long as you respect it and cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. This is educational and research material only, but if you track MRNA, treat every headline — from Nasdaq‑100 flows to oncology data to C‑suite changes — as a potential trigger, and trade the price action, not the hype.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”